Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma

Akiko Mizote, Akira I. Hida, Mutsumi Hosako, Masayoshi Fujisawa, Mika Kamekawa, Shigeru Okada

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The ferric nitrilotriacetate-induced carcinogenesis model is unique in that reactive oxygen species-free radicals are involved in the carcinogenic process. But the effects of iron-withdrawal in the progression of renal cell carcinoma are not well understood. We performed repeated phlebotomies on animals that had been administered ferric nitrilotriacetate in the initiation stage of renal cell carcinoma (phlebotomy group), and compared the development of renal tumors with those not receiving repeated phlebotomies (non-phlebotomy group). Ferric nitrilotriacetate-treated male Wistar rats were randomly divided into 2 groups: a phlebotomy group (21 rats) and a non-phlebotomy group (17 rats). Ten age-adjusted normal rats were also observed as a normal group. Hematocrit was maintained under 25% in the phlebotomy group. Hematocrit levels in the normal group and in the non-phlebotomy group were not significantly different. As a result, the incidence of renal cell carcinoma was not significantly different between phlebotomy and non-phlebotomy animals. However, the total weight of the renal cell carcinoma was significantly heavier in the animals from non-phlebotomy group than in those from the phlebotomy group (23.64 g ± 18.54 vs. 54.40 g ± 42.40, P <0.05). The present study demonstrated that phlebotomy after the administration of ferric nitrilotriacetate did not reduce the incidence of renal cell carcinoma. In addition, we showed that iron withdrawal at the promotion stage of carcinogenesis will retard tumor growth.

Original languageEnglish
Pages (from-to)199-204
Number of pages6
JournalActa Medica Okayama
Volume56
Issue number4
Publication statusPublished - 2002

Fingerprint

Phlebotomy
Renal Cell Carcinoma
Cells
Rats
Growth
Animals
Tumors
Iron
Hematocrit
Carcinogenesis
Free Radicals
Reactive Oxygen Species
ferric nitrilotriacetate
Incidence
Wistar Rats
Neoplasms
Kidney
Weights and Measures

Keywords

  • Ferric nitrilotriacetate
  • Phlebotomy
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mizote, A., Hida, A. I., Hosako, M., Fujisawa, M., Kamekawa, M., & Okada, S. (2002). Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma. Acta Medica Okayama, 56(4), 199-204.

Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma. / Mizote, Akiko; Hida, Akira I.; Hosako, Mutsumi; Fujisawa, Masayoshi; Kamekawa, Mika; Okada, Shigeru.

In: Acta Medica Okayama, Vol. 56, No. 4, 2002, p. 199-204.

Research output: Contribution to journalArticle

Mizote, A, Hida, AI, Hosako, M, Fujisawa, M, Kamekawa, M & Okada, S 2002, 'Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma', Acta Medica Okayama, vol. 56, no. 4, pp. 199-204.
Mizote, Akiko ; Hida, Akira I. ; Hosako, Mutsumi ; Fujisawa, Masayoshi ; Kamekawa, Mika ; Okada, Shigeru. / Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma. In: Acta Medica Okayama. 2002 ; Vol. 56, No. 4. pp. 199-204.
@article{1bc9331140a84a13834a90da4662d6de,
title = "Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma",
abstract = "The ferric nitrilotriacetate-induced carcinogenesis model is unique in that reactive oxygen species-free radicals are involved in the carcinogenic process. But the effects of iron-withdrawal in the progression of renal cell carcinoma are not well understood. We performed repeated phlebotomies on animals that had been administered ferric nitrilotriacetate in the initiation stage of renal cell carcinoma (phlebotomy group), and compared the development of renal tumors with those not receiving repeated phlebotomies (non-phlebotomy group). Ferric nitrilotriacetate-treated male Wistar rats were randomly divided into 2 groups: a phlebotomy group (21 rats) and a non-phlebotomy group (17 rats). Ten age-adjusted normal rats were also observed as a normal group. Hematocrit was maintained under 25{\%} in the phlebotomy group. Hematocrit levels in the normal group and in the non-phlebotomy group were not significantly different. As a result, the incidence of renal cell carcinoma was not significantly different between phlebotomy and non-phlebotomy animals. However, the total weight of the renal cell carcinoma was significantly heavier in the animals from non-phlebotomy group than in those from the phlebotomy group (23.64 g ± 18.54 vs. 54.40 g ± 42.40, P <0.05). The present study demonstrated that phlebotomy after the administration of ferric nitrilotriacetate did not reduce the incidence of renal cell carcinoma. In addition, we showed that iron withdrawal at the promotion stage of carcinogenesis will retard tumor growth.",
keywords = "Ferric nitrilotriacetate, Phlebotomy, Renal cell carcinoma",
author = "Akiko Mizote and Hida, {Akira I.} and Mutsumi Hosako and Masayoshi Fujisawa and Mika Kamekawa and Shigeru Okada",
year = "2002",
language = "English",
volume = "56",
pages = "199--204",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Effects of phlebotomy on the growth of ferric nitrilotriacetate-induced renal cell carcinoma

AU - Mizote, Akiko

AU - Hida, Akira I.

AU - Hosako, Mutsumi

AU - Fujisawa, Masayoshi

AU - Kamekawa, Mika

AU - Okada, Shigeru

PY - 2002

Y1 - 2002

N2 - The ferric nitrilotriacetate-induced carcinogenesis model is unique in that reactive oxygen species-free radicals are involved in the carcinogenic process. But the effects of iron-withdrawal in the progression of renal cell carcinoma are not well understood. We performed repeated phlebotomies on animals that had been administered ferric nitrilotriacetate in the initiation stage of renal cell carcinoma (phlebotomy group), and compared the development of renal tumors with those not receiving repeated phlebotomies (non-phlebotomy group). Ferric nitrilotriacetate-treated male Wistar rats were randomly divided into 2 groups: a phlebotomy group (21 rats) and a non-phlebotomy group (17 rats). Ten age-adjusted normal rats were also observed as a normal group. Hematocrit was maintained under 25% in the phlebotomy group. Hematocrit levels in the normal group and in the non-phlebotomy group were not significantly different. As a result, the incidence of renal cell carcinoma was not significantly different between phlebotomy and non-phlebotomy animals. However, the total weight of the renal cell carcinoma was significantly heavier in the animals from non-phlebotomy group than in those from the phlebotomy group (23.64 g ± 18.54 vs. 54.40 g ± 42.40, P <0.05). The present study demonstrated that phlebotomy after the administration of ferric nitrilotriacetate did not reduce the incidence of renal cell carcinoma. In addition, we showed that iron withdrawal at the promotion stage of carcinogenesis will retard tumor growth.

AB - The ferric nitrilotriacetate-induced carcinogenesis model is unique in that reactive oxygen species-free radicals are involved in the carcinogenic process. But the effects of iron-withdrawal in the progression of renal cell carcinoma are not well understood. We performed repeated phlebotomies on animals that had been administered ferric nitrilotriacetate in the initiation stage of renal cell carcinoma (phlebotomy group), and compared the development of renal tumors with those not receiving repeated phlebotomies (non-phlebotomy group). Ferric nitrilotriacetate-treated male Wistar rats were randomly divided into 2 groups: a phlebotomy group (21 rats) and a non-phlebotomy group (17 rats). Ten age-adjusted normal rats were also observed as a normal group. Hematocrit was maintained under 25% in the phlebotomy group. Hematocrit levels in the normal group and in the non-phlebotomy group were not significantly different. As a result, the incidence of renal cell carcinoma was not significantly different between phlebotomy and non-phlebotomy animals. However, the total weight of the renal cell carcinoma was significantly heavier in the animals from non-phlebotomy group than in those from the phlebotomy group (23.64 g ± 18.54 vs. 54.40 g ± 42.40, P <0.05). The present study demonstrated that phlebotomy after the administration of ferric nitrilotriacetate did not reduce the incidence of renal cell carcinoma. In addition, we showed that iron withdrawal at the promotion stage of carcinogenesis will retard tumor growth.

KW - Ferric nitrilotriacetate

KW - Phlebotomy

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0036689559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036689559&partnerID=8YFLogxK

M3 - Article

C2 - 12199525

AN - SCOPUS:0036689559

VL - 56

SP - 199

EP - 204

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -